拥有与众不同的创新思维

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces it has entered into an agreement with two European partners to complete a late-stage research and development programme for a novel injectable medicine containing a patented New Chemical Entity (NCE). The conditional agreement envisages AFT undertaking a final confirmatory Phase III clinical trial of the medicine involving […]

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an Agreement with Hikma Pharmaceuticals USA (“Hikma”) to distribute its patented1 COMBOGESIC® Tablets, a fixed dose combination (FDC) (acetaminophen and ibuprofen), non-opioid analgesia in a single tablet for adult pain management to select markets in the United States, the largest pharma market in the world.2 The Agreement […]

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazil.